A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)
Latest Information Update: 24 Sep 2026
At a glance
- Drugs Venetoclax (Primary) ; Azacitidine; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Registrational; Therapeutic Use
- Acronyms Verona
- Sponsors AbbVie; AbbVie Germany
Most Recent Events
- 06 May 2026 Planned End Date changed from 1 Mar 2026 to 1 Jul 2027.
- 06 May 2026 Planned primary completion date changed from 1 Mar 2026 to 1 Jul 2027.
- 06 Dec 2025 According to a Dana Farber Cancer Institute media release, Dana-Farber Cancer Institute's Dr. Jacqueline S. Garcia, is a principal investigator of this study.